Recruiting

Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II

ClinicalTrials.gov IDNCT06706791

PhasePHASE4

Enrollment156

SponsorFazaia Ruth Pfau Medical College

Age40 Years

SexALL

I'm interested View official listing

Conditions studied

Chronic Heart Failure

About this study

Effect of Empagliflozin on Quality of Life in patient of Chronic Heart Failure with Diabetes Mellitus Type II. As per ESC Guidelines Empagliflozin is recommended as part of the first-line treatment for HFrEF, irrespective of diabetes status. As per American College of Cardiology (ACC)/American Heart Association (AHA) Empagliflozin is recommended in both diabetic and non-diabetic HF (especially beneficial in patients with HFrEF and HFpEF). The aim of my study is to assess the impact of Empagliflozin on quality of life in Pakistani patients, considering the genetic, environmental and cultural factors. The study will also explore whether Empagliflozin can offer cost-effective option for managing chronic heart failure and diabetes, potentially reducing the economic burden on both patients and health care system.

Interventions

Drug: Empagliflozin 10 MG — participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.

Primary outcomes

improvement in Kansas city cardiomyopathy questionnaire scoring (18 months)

Eligibility information

Inclusion Criteria: 1. Age 40-70 years at time of screening. 2. Both Men and women are included in study. 3. Patients with chronic heart failure and currently categorized in class II-IV heart failure as per NHYA classification having ejection fraction less than 40%. 4. Patients having NT- proBNP levels greater than 25pg/ml. 5. Diabetic patient diagnosed (HbA1c \> 6.5mg/dl) and currently taking antidiabetic medicine. Exclusion Criteria: 1. Pregnant female. 2. Patient with end stage renal disease (ESRD). 3. Patient with acute decompensated heart failure. 4. Acute coronary syndrome patients.

Study locations

Fazaia Ruth Pfau Hospital, Karachi, Sindh 75120 Pakistan

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.